(Journal Article): A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity
 
Qin HY, Mukherjee R, Lee-Chan E, Ewen C, Bleackley RC, Singh B (Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, N6A 5C1, Canada.)
 
IN: Int Immunol 2006; 18(7):1001-1015
Impact Factor(s) of Int Immunol: 3.543 (2004), 3.69 (2003), 3.595 (2002), 3.611 (2001)

Fulltext:    HTML  PDF

ABSTRACT: We have established a novel CD4 and CD8 double-positive CD25+ T regulatory (Treg) clone, MT-5B, from lymph nodes of type 1 diabetes prone non-obese diabetic (NOD) mice immunized with CFA. CFA has previously been shown to prevent the onset of diabetes by inducing Treg cells. In vitro, clone MT-5B was anergic to a panel of antigen stimulations and exerted an immunosuppressive effect in antigen-non-specific and cell contact-independent manners. In vivo, clone MT-5B blocked the adoptive transfer of diabetes. Proteomics and immunoadsorption studies identified the suppressive proteins secreted by clone MT-5B as granzyme B (GrB) and perforin (PFN). GrB-mediated immune suppression was PFN dependent. Removal of GrB or PFN from the culture supernatant (SN) of MT-5B cells or pre-incubation of MT-5B cells with ethyleneglycol-bis(aminoethylether)-tetraacetic acid which blocks PFN activity reduced the immunosuppressive effect in vitro. Pre-incubation of diabetogenic splenocytes from NOD mice with MT-5B SN impaired their ability to transfer disease by inducing T cell apoptosis, and removal of GrB from MT-5B SN by immunoadsorption decreased the effector function of MT-5B SN on diabetogenic splenocytes. Immunization of NOD mice with CFA increased the expression of GrB+ CD4 T cells, indicating that these cells are present in vivo. In conclusion, we describe a novel mechanism of cell contact-independent immune suppression in which Treg cells maintain immune homeostasis by secreting GrB/PFN.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self tolerance and negative control of immune responses. Annu Rev Immunol 2004. 22:531.
2. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998. 160:1212.
3. Bluestone JA and Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003. 3:253.
4. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003. 81:331.
5. Mukherjee R, Chaturvadi P, Qin HY, Singh B. CD4+CD25+ regulatory T cells generated in response to insulin B: 9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells. J Autoimmun 2003. 21:221.
6. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995. 150:1151.
7. Thornton AM and Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000. 164:183.
8. Groux H, O'Garra A, Bigle M, Rouleau M, Antonenko S, de Vries JE. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997. 389:737.
9. Levings MK and Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 2000. 106:109.
10. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001. 3:947.
11. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001. 182:18.
12. Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol 2004. 16:135.
13. Chaturvedi P, Qin HY, Chou H, Singh B. Modulation of insulin-dependent diabetes mellitus (IDDM) in NOD mice by autoreactive T cells. Crit Rev Immunol 1997. 17:519.
14. Han HS, Jun HS, Utsugi T, Yoon JW. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996. 9:331.
15. Akhtar I, Gold JP, Pan LY, Ferrara JL, Yang XD, Kim JI, Tan KN. CD4+ beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 1995. 182:87.
16. Judes AE and von Herrath MG. Regulatory T-cells in type 1 diabetes. Diabetes Metab Res Rev 2004. 20:446.
17. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001. 194:629.
18. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003. 100:10878.
19. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000. 192:295.
20. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002. 16:311.
21. Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, Shevach EM. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 2002. 196:237.
22. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002. 196:1335.
23. Jonuleit H and Schmitt E. The regulatory T cell family: distinct subset and their interrelations. J Immunol 2003. 171:6323.
24. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003. 299:1057.
25. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003. 4:330.
26. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003. 3:361.
27. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003. 193:31.
28. Russell JH and Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002. 20:323.
29. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004. 21:589.
30. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005. 174:1783.
31. Yagita H, Nakata M, Kawasaki A, Shinkai Y, Okumura K. Role of perforin in lymphocyte-mediated cytolysis. Adv Immunol 1992. 51:215.
32. Shi L, Keefe D, Durand E, Feng H, Zhang D, Lieberman J. Granzyme B binding to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol 2005. 174:5456.
33. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000. 103:491.
34. Metkar SS, Wang B, Aguilar-Santelises M, Raja SM, Uhlin-Hansen L, Podack E, Trapani JA, Froelich CJ. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 2002. 16:417.
35. Raja SM, Metkar SS, Froelich CJ. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr Opin Immunol 2003. 15:528.
36. Sadelain MW, Qin HY, Lauzon J, Singh B. Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990. 39:583.
37. Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 1993. 150:2072.
38. Ewen C, Kane KP, Shostak I, Griebel PJ, Bertram EM, Watts TH, Bleackley RC, McElhaney JE. A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for granzyme B. J Immunol Methods 2003. 276:89.
39. Takayama H and Sitkovsky MV. Antigen receptor-regulation in cytotoxic T lymphocytes. J Exp Med 1987. 166:725.
40. Baetz K, Isaaz S, Griffiths M. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretary defect that prevents lytic granule exocytosis. J Immunol 1995. 154:6122.
41. van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT, Wertheim-van Dillen PM, van Lier RA, ten Berge IJ. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004. 173:1834.
42. Lauw FN, Simpson AJ, Hack CE, Prins JM, Wolbink AM, van Deventer SJ, Chaowagul W, White NJ, van Der Poll T. Soluble granzymes are released during human endotoxemia in patients with sever infection due to gram-negative bacteria. J Infect Dis 2000. 182:206.
43. Murray PD, McGavern DB, Lin X, Njenga MK, Leibowitz J, Pease LR, Rodriguez M. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 1998. 1:7306.
44. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, Easterbrook P, Grey P, Smith D, McMichael AJ, Cooper DA, Rowland-Jones SL, Kelleher AD. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002. 168:5954.
45. Norris PJ, Sumaroka M, Brander C, Moffett HF, Boswell SL, Nguyen T, Sykulev Y, Walker BD, Rosenberg ES. Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 2001. 75:9771.
46. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 2002. 99:3302.
47. Yawalkar N, Schmid S, Braathen LR, Pichler WJ. Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis. Br J Dermatol 2001. 144:1133.
48. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004. 104:906.
49. Suni MA, Ghanekar SA, Houck DW, Maecker HT, Wormsley SB, Picker LJ, Moss RB, Maino VC. CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 2001. 31:2512.
50. Nam K, Akari H, Terao K, Shibata H, Kawamura S, Yoshikawa Y. Peripheral blood extrathymic CD4(+)CD8(+) T cells with high cytotoxic activity are from the same lineage as CD4(+)CD8(-) T cells in cynomolgus monkeys. Int Immunol 2000. 12:1095.
51. Zuckermann FA. Extrathymic CD4/CD8 double positive T cells. Vet Immunol Immunopathol 1999. 72:55.
52. Kenny E, Mason D, Pombo A, Ramirez F. Phenotypic analysis of peripheral CD4+CD8+ T cells in the rat. Immunology 2000. 101:178.
53. Kenny E, Mason D, Saoudi A, Pombo A, Ramirez F. CD8{alpha} is an activation marker for subset of peripheral CD4 T cells. Eur J Immunol 2004. 34:1262.
54. Krajina T, Leithauser F, Reimann J. MHC class II-independent CD25+CD4+ CD8alpha beta+ alpha beta T cells attenuate CD4+ T cell-induced transfer colitis. Eur J Immunol 2004. 34:705.
55. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. Blood 2004. 104:478.
56. Rabinovich BA, Li J, Shannon J, Hurren R, Chalupny J, Cosman D, Miller RG. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003. 170:3572.
57. Kaneko T. Human autoreactive (Th0) CD4(+) T-cell clones with cytolytic activity recognizing autologous activated T cells as the target. Hum Immunol 2000. 61:780.
58. Shevach EM, Piccirillo CA, Thornton AM, McHugh RS. Control of T cell activation by CD4+CD25+ suppressor T cells. Novartis Found Symp 2003. 252:24.
59. Bushell A, Jones E, Gallimore A, Wood K. The generation of CD25+CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005. 174:3290.
60. Malipiero U, Frei K, Spanaus KS, Agresti C, Lassmann H, Hahne M, Tschopp J, Eugster HP, Fontana A. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur J Immunol 1997. 27:3151.
61. Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol 2004. 16:1723.
62. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2003. 2:1341.
63. Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing Foxp3 and TGFß1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005. 201:1333.
64. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004. 34:336.